THNR
Amplify Weight Loss Drug & Treatment ETFNYSE
Updated 1 day ago
Coverage building
$24.03-1.61%
Close Oct 13, 2026
- Market cap
- —
- 1 month
- -6.7%
- 3 months
- -7.2%
- 1 year
- +0.7%
- 52-week range
- $22.94$27.91
- Dividend
- No dividends on record
- Short interest
- 3K sharessettled Sep 30, 2026 · -13.3% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if THNR is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Institutional coverage is still building for this ticker.
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
4 filers reported a long position in THNR for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| CITADEL ADVISORS LLC | $706.3K | 27.5K | +0.9% |
| JANE STREET GROUP, LLC | $450K | 17.5K | New |
| OSAIC HOLDINGS, INC. | $9.1K | 356 | New |
| Godfrey Financial Associates, Inc. | $5.2K | 203 | Unchanged |
Get the Full Analysis for THNR
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.